18F PET with florbetapir for the early diagnosis of Alzheimer’s disease dementia and other dementias in people with mild cognitive impairment (MCI)-Reference-Cited by-同舟云学术

18F PET with florbetapir for the early diagnosis of Alzheimer’s disease dementia and other dementias in people with mild cognitive impairment (MCI)

Published:2017-11-22 Issue:11 Volume:2017 Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Martínez Gabriel¹²³,Vernooij Robin WM¹,Fuentes Padilla Paulina¹²,Zamora Javier⁴,Bonfill Cosp Xavier⁵⁶,Flicker Leon⁷

Affiliation:

1. Iberoamerican Cochrane Centre; C/ Sant Antoni Maria Claret 167 Pavelló 18 Planta 0 Barcelona Barcelona Spain 08025

2. Universidad de Antofagasta; Faculty of Medicine and Dentistry; Antofagasta Chile

3. Institut Català de Neurociències Aplicades; Alzheimer Research Center and Memory Clinic of Fundació ACE; Barcelona Spain

4. Ramon y Cajal Institute for Health Research (IRYCIS), CIBER Epidemiology and Public Health (CIBERESP), Madrid (Spain) and Women's Health Research Unit, Centre for Primary Care and Public Health, Queen Mary University of London; Clinical Biostatistics Unit; London Madrid UK

5. CIBER Epidemiología y Salud Pública (CIBERESP); Iberoamerican Cochrane Centre, Biomedical Research Institute Sant Pau (IIB Sant Pau); Sant Antoni Maria Claret 167 Pavilion 18 Barcelona Catalunya Spain 08025

6. Universitat Autònoma de Barcelona; Sant Antoni Maria Claret, 167 Pavilion 18 (D-13) Barcelona Catalunya Spain 08025

7. University of Western Australia; Western Australian Centre for Health & Ageing - WACHA; Crawley Perth Western Australia Australia 6014

Publisher

Wiley

Subject

Pharmacology (medical)

Reference161 articles.

1. Prognostic significance of florbetapir F18 PET imaging in MCI and mormal elderly: final results from a longitudinal multicenter trial;Doraiswamy;Alzheimer's & Dementia,2011

2. Amyloid-β assessed by florbetapir F 18 PET and 18-month cognitive decline: a multicenter study;Doraiswamy;Neurology,2012

3. Florbetapir F 18 amyloid PET and 36-month cognitive decline: a prospective multicenter study;Doraiswamy;Molecular Psychiatry,2014

4. Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimer's disease dementia, mild cognitive impairment, and normal aging;Johnson;Alzheimer's & Dementia,2013

5. NCT00857506 Observational study of cognitive outcomes for subjects who have had prior PET amyloid imaging With Florbetapir F 18 (18F-AV-45) https://clinicaltrials.gov/show/NCT00857506

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Scottish Intercollegiate Guidelines Network Guidance on Dementia: The Investigation of Suspected Dementia (SIGN 168) with Focus on Biomarkers—Executive Summary;Thrombosis and Haemostasis;2024-05-24

2. Multiomics Blood-Based Biomarkers Predict Alzheimer’s Predementia with High Specificity in a Multicentric Cohort Study;The Journal of Prevention of Alzheimer's Disease;2024

3. Neurodegenerative und Demenzielle Erkrankungen;PET/CT-Atlas;2024

4. Biological Diagnosis of Alzheimer’s Disease Based on Amyloid Status: An Illustration of Confirmation Bias in Medical Research?;International Journal of Molecular Sciences;2023-12-16

5. The Quantum-Medical Nexus: Understanding the Impact of Quantum Technologies on Healthcare;Cureus;2023-10-31